The Pharma Deal Strategy Challenge
A mid-sized life sciences manufacturing company with new cell lines developed a novel pipeline and they sought the partnership of a global or several regional pharmaceutical companies with strong competencies in clinical development and marketing in the focus therapy areas. However, the company had no clear understanding regarding the value the selected compounds were worth and how that value should be shared with their future partners.
Following a detailed valuation phase, PharmaVentures conducted a comprehensive pharma deal strategy benchmarking analysis using PharmaDeals Agreements proprietary data to evaluate the possible deal outcomes and to identify three deal structures for the client: “Optimal”, “Fall-back” and “Walk-away” positions. The developed deal structures were assessed for returns to the client across the life cycle of the products as well as regional versus global partnerships.